Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Shiyu Capital Closes Second China Healthcare Fund with $473 Million

publication date: Apr 11, 2019

Shiyu Capital of Shenzhen closed its second China life science PE fund with $473 million in capital. The fund, called Danqing Fund II, will invest in pharma/biotech, healthcare, IVD and medical services companies. The Danqing funds aim to participate in the "historic opportunity" of transforming China's pharmaceutical industry. The company's first fund, launched in 2016, raised $164 million. Both funds are RMB denominated. Shiyu Capital, also known as Shenzhen Shiyu Investment Management, was established in 2014. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital